MEP38808A - Use of lh in controlled ovarian hyperstimulation - Google Patents
Use of lh in controlled ovarian hyperstimulationInfo
- Publication number
- MEP38808A MEP38808A MEP-388/08A MEP38808A MEP38808A ME P38808 A MEP38808 A ME P38808A ME P38808 A MEP38808 A ME P38808A ME P38808 A MEP38808 A ME P38808A
- Authority
- ME
- Montenegro
- Prior art keywords
- ovarian hyperstimulation
- controlled ovarian
- coh
- controlled
- folliculogenesis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01307755 | 2001-09-12 | ||
PCT/GB2002/004147 WO2003022301A2 (en) | 2001-09-12 | 2002-09-12 | Use of lh in controlled ovarian hyperstimulation |
Publications (1)
Publication Number | Publication Date |
---|---|
MEP38808A true MEP38808A (en) | 2011-02-10 |
Family
ID=8182260
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MEP-388/08A MEP38808A (en) | 2001-09-12 | 2002-09-12 | Use of lh in controlled ovarian hyperstimulation |
Country Status (28)
Country | Link |
---|---|
US (1) | US7341989B2 (xx) |
EP (1) | EP1434600B1 (xx) |
JP (1) | JP2005504072A (xx) |
KR (1) | KR20040032953A (xx) |
CN (1) | CN1302806C (xx) |
AR (1) | AR036591A1 (xx) |
AT (1) | ATE427755T1 (xx) |
AU (1) | AU2002331939B2 (xx) |
BR (1) | BR0212502A (xx) |
CA (1) | CA2457067A1 (xx) |
CY (1) | CY1110487T1 (xx) |
DE (1) | DE60231892D1 (xx) |
DK (1) | DK1434600T3 (xx) |
EA (1) | EA009210B1 (xx) |
ES (1) | ES2322136T3 (xx) |
HK (1) | HK1067866A1 (xx) |
HR (1) | HRP20040070A2 (xx) |
IL (1) | IL160781A0 (xx) |
ME (1) | MEP38808A (xx) |
MX (1) | MXPA04002125A (xx) |
NO (1) | NO327154B1 (xx) |
PL (1) | PL205472B1 (xx) |
PT (1) | PT1434600E (xx) |
RS (1) | RS51505B (xx) |
SI (1) | SI1434600T1 (xx) |
UA (1) | UA78970C2 (xx) |
WO (1) | WO2003022301A2 (xx) |
ZA (1) | ZA200401008B (xx) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL373991A1 (en) * | 2002-06-07 | 2005-09-19 | Ares Trading S.A. | Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method |
US20040248784A1 (en) * | 2003-06-03 | 2004-12-09 | Marco Filicori | Unitary combinations of FSH and hCG |
CN102296047B (zh) * | 2011-08-13 | 2013-03-13 | 新疆农垦科学院 | 利用羔羊超排卵母细胞生产体外胚胎的方法 |
US9216037B2 (en) | 2013-06-21 | 2015-12-22 | Previvo Genetics, Llc | Uterine lavage for embryo retrieval |
US9282995B2 (en) * | 2011-12-22 | 2016-03-15 | Previvo Genetics, Llc | Recovery and processing of human embryos formed in vivo |
US20150272622A1 (en) | 2011-12-22 | 2015-10-01 | Previvo Genetics, Llc | Recovery and processing of human embryos formed in vivo |
US20160024181A1 (en) | 2013-03-13 | 2016-01-28 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
RU2629871C1 (ru) * | 2016-03-22 | 2017-09-04 | Сергей Михайлович Юдин | Препарат для стимуляции фолликулогенеза и способ его применения |
IT202000022015A1 (it) * | 2020-09-18 | 2022-03-18 | Marca Antonio La | Nuovo uso dell'ormone luteinizzante |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4589402A (en) | 1984-07-26 | 1986-05-20 | Serono Laboratories, Inc. | Method of in vitro fertilization |
IT1250075B (it) * | 1991-12-18 | 1995-03-30 | Serono Cesare Ist Ricerca | Composizioni farmaceutiche contenenti gonadotropine. |
ES2267531T5 (es) * | 1999-05-07 | 2015-11-24 | Merck Serono Sa | Uso de LH administrada en la fase folicular media o tardía para el tratamiento de mujeres anovulatorias |
-
2002
- 2002-09-12 AU AU2002331939A patent/AU2002331939B2/en not_active Ceased
- 2002-09-12 PL PL367343A patent/PL205472B1/pl unknown
- 2002-09-12 WO PCT/GB2002/004147 patent/WO2003022301A2/en active Application Filing
- 2002-09-12 BR BR0212502-1A patent/BR0212502A/pt not_active Application Discontinuation
- 2002-09-12 IL IL16078102A patent/IL160781A0/xx unknown
- 2002-09-12 EP EP02767637A patent/EP1434600B1/en not_active Revoked
- 2002-09-12 PT PT02767637T patent/PT1434600E/pt unknown
- 2002-09-12 DE DE60231892T patent/DE60231892D1/de not_active Expired - Lifetime
- 2002-09-12 CA CA002457067A patent/CA2457067A1/en not_active Withdrawn
- 2002-09-12 KR KR10-2004-7002589A patent/KR20040032953A/ko not_active Application Discontinuation
- 2002-09-12 RS YUP-212/04A patent/RS51505B/sr unknown
- 2002-09-12 DK DK02767637T patent/DK1434600T3/da active
- 2002-09-12 AT AT02767637T patent/ATE427755T1/de active
- 2002-09-12 CN CNB028175743A patent/CN1302806C/zh not_active Expired - Fee Related
- 2002-09-12 ME MEP-388/08A patent/MEP38808A/xx unknown
- 2002-09-12 AR ARP020103455A patent/AR036591A1/es not_active Application Discontinuation
- 2002-09-12 MX MXPA04002125A patent/MXPA04002125A/es active IP Right Grant
- 2002-09-12 ES ES02767637T patent/ES2322136T3/es not_active Expired - Lifetime
- 2002-09-12 EA EA200400428A patent/EA009210B1/ru not_active IP Right Cessation
- 2002-09-12 US US10/487,423 patent/US7341989B2/en not_active Expired - Fee Related
- 2002-09-12 JP JP2003526429A patent/JP2005504072A/ja active Pending
- 2002-09-12 SI SI200230815T patent/SI1434600T1/sl unknown
- 2002-12-09 UA UA2004031858A patent/UA78970C2/uk unknown
-
2004
- 2004-01-23 HR HR20040070A patent/HRP20040070A2/hr not_active Application Discontinuation
- 2004-02-06 ZA ZA2004/01008A patent/ZA200401008B/en unknown
- 2004-03-08 NO NO20040990A patent/NO327154B1/no not_active IP Right Cessation
-
2005
- 2005-02-22 HK HK05101453A patent/HK1067866A1/xx not_active IP Right Cessation
-
2009
- 2009-06-30 CY CY20091100694T patent/CY1110487T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2130574T3 (es) | Agentes de restriccion de las citoquinas. | |
MEP38808A (en) | Use of lh in controlled ovarian hyperstimulation | |
BR9106702A (pt) | Analogo de oligonucleotideos e processos para modular a producao de uma proteina por um organismo e para tratar um organismo | |
BR9006729A (pt) | Dispositivo de reforco e de sustentacao da capa dos rotadores de uma articulacao de ombro humano | |
HUP0003349A2 (hu) | Mellékpajzsmirigy-hormon peptidanalógok, ezeket hatóanyagként tartalmazó gyógyászati készítmények és alkalmazásuk | |
DE69839812D1 (de) | Analoge des menschlichen interferon-alpha mit niedriger toxizität | |
DE69930758D1 (de) | Verwendung von daptomycin | |
ATE192037T1 (de) | Verwendung von arginin als immunstimulator | |
KR950031060A (ko) | 골다공증 치료용 약제학적 조성물 | |
PT1001802E (pt) | Preparacao farmaceutica combinada compreendendo a hormona da paratiroide e um inibidor de reabsorcao ossea | |
ATE238986T1 (de) | 1,3-dihydroxy-20,20-dialkyl-vitamin d3 analoga | |
DK0678013T3 (da) | Præparater til behandling af hår | |
ES2135398T3 (es) | Compuesto y composiciones de inhibicion de la resorcion osea. | |
RS50805B (sr) | Upotreba fsh za lečenje neplodnosti | |
DE69630583D1 (de) | Peptide, bronchodilator und den blutstrom verbesserndes mittel | |
ES2108122T3 (es) | Composicion a base de amilina o de un analogo de amilina conteniendo opcionalmente insulina, para el tratamiento de la anorexia y de las patologias asociadas. | |
ATE398134T1 (de) | Neue analoga von nitrobenzylthioinosin | |
FR2632525B1 (fr) | Application therapeutique de la myeloperoxydase humaine | |
ATE433749T1 (de) | Neue verwendung von rapamycin und strukturellen analoga hiervon | |
KR950013519A (ko) | 골절 예방 및 치료용 약제 | |
ATE374202T1 (de) | Neue analoga von nitrobenzylthioinosin | |
DK1007085T3 (da) | Anvendelse af væksthormon i præparater til behandling af insulin-resistens i hjertet | |
EA201000501A1 (ru) | Фармацевтическая композиция, содержащая не обладающий нейротоксичностью активатор плазминоген для лечения удара | |
BR0212274A (pt) | Uso de estrogênios não-feminilizantes como agentes retinoprotetores para o tratamento de glaucoma | |
ATE412669T1 (de) | Calicitonin-analoga mit stark erhöhter hypocalcämischer wirkung in vivo |